Do you want to read an article? Please log in or register.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Cardiovascular Risk and DiseasesMyocardial InfarctionThrombosis and StrokeTherapy and Intervention
Related content
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
JAMA Cardiol.
Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ
doi: 10.1001/
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering DrugsMyocardial InfarctionThrombosis and Stroke
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
JAMA Cardiol.
Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS
doi: 10.1001/jamacardio.
Cardiovascular Risk and DiseasesThrombosis and Stroke
Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus
Circulation
Capodanno D, Angiolillo DJ
doi: 10.1161/CIRCULATIONAHA.120.045465
Heart, Artery and Coronary DiseasesThrombosis and StrokeTherapy and Intervention
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)
Eur Heart J.
Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL
doi: 10.1093/eurheartj/ehx419.
Heart, Artery and Coronary DiseasesThrombosis and Stroke
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease
Am Heart J.
Welsh RC, Peterson ED, De Caterina R, Bode C, Gersh B, Eikelboom JW
doi: 10.1016/j.ahj.2019.09.006.
Lipid-Lowering DrugsMyocardial InfarctionTherapy and Intervention
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
N Engl J Med.
HPS3/TIMI55-REVEAL Collaborative Group
doi: 10.1056/NEJMoa1706444.
RECOMMENDED
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc
Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana JS, Wagner J, Philip S, Abrahamson D, Granowitz C, Go AS
doi: 10.1161/JAHA.120.020377
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease
JAMA Cardiol.
Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA
doi: 10.1001/
Heart, Artery and Coronary Diseases
Optimal Medical Therapy for Known Coronary Artery Disease: A Review
JAMA Cardiol.
Gibbons RJ, Miller TD
doi: 10.1001/